Life science and software companies depend on patents to protect their innovations. Yet, over the last six years, the Supreme Court has greatly restricted the scope of what can be patented. The new eligibility standards have proven difficult for the USPTO to apply and have led to unpredictable patenting outcomes. Many businesses find the USPTO unwilling to grant commercially viable patents on a wide variety of formerly patentable subject matter including diagnostics, software, and natural products from DNA to potential new drugs.
BioForward & Foley & Lardner held the first local panel discussion on topics including: how these Supreme Court rulings have impacted patent eligibility, what the new 2018 USPTO guidance addresses, how this could change what can be patented, and tips on how to use the new guidelines to your advantage.
7:30-8:00 AM: Networking and Light Breakfast
8:00-9:00 AM: Patenting Guideline Updates from Foley & Lardner Panel
9:00-9:30 AM: Networking